publication date: Oct. 21, 2016
Issue 39 - Oct. 21, 2016
  • Biden Delivers Task Force Report—

    Five Moonshot Goals in Cancer

    Vice President Joe Biden and the National Cancer Moonshot Task Force published their final reports Oct. 17, summarizing the moonshot’s achievements, and outlining five strategic goals and action plans for the years to come.

    The two reports conclude the 2016 National Cancer Moonshot Initiative, and the Obama administration’s efforts to develop a national conversation on cancer research.

  • Obama: The Moonshot, “Architecture and a Framework” for Cancer Research

    President Barack Obama accepted Vice President Joe Biden and the National Cancer Moonshot Task Force’s reports—blueprints for how the federal government should focus on cancer research, oncology bioinformatics, and patient access and care over the next few years.

    “This all comes down to, ‘How does it impact patients?’ And so Joe, I think, has done a great job in engaging people who are going through battling cancer right now, and finding ways that we’re not just coming up with cures, but we’re also making sure that these systems are set up so that they’re easier for people to access,’ Obama said at a press conference Oct. 17.

  • LLS Starts Beat AML Master Trial

    After four decades of few improvements in the treatment for acute myeloid leukemia, the Leukemia and Lymphoma Society has launched a precision medicine trial to identify targeted treatments for patients with AML.

    The society’s trial—called Beat AML Master Trial—was announced by Vice President Joe Biden Oct. 17 at a White House event rolling out Moonshot-related initiatives.

  • Califf, Bach, Jasin, Offit, Venter Among New Members of NAM

    The National Academy of Medicine announced today the election of 70 regular members and nine international members during its annual meeting. 

    The NAM Articles of Organization stipulate that at least one-quarter of the membership is selected from fields outside the health professions.

  • In Brief

    • Fuchs Named Director at Yale
    • Cox Wins Statistics Top Prize
    • David Cella received National Academy of Medicine Gustav O. Lienhard Award
    • Marcio Fagundes and Michael Chuong joined the Miami Cancer Institute at Baptist Health South Florida’s integrated Radiation Oncology Department
    • The Robert H. Lurie Comprehensive Cancer Center announced a partnership that will make Tempus as a preferred partner
    • Leidos Biomedical Research, Inc. awarded ATCC
    • Carol Burke elected president of the American College of Gastroenterology
    • The Pan Mass Challenge raised $47 million
    • The Scripps Research Institute and the California Institute for Biomedical Research announced the signing of a strategic affiliation
  • Drugs and Targets

    • Lartruvo gets accelerated approval for sarcoma
    • Tecentriq approved for a type of NSCLC
    • Venclyxto granted a positive opinion from the European Committee for Medicinal Products for Human Use
    • Onivyde in combination with 5-fluorouracil and leucovorin received marketing authorization from The European Commission
    • CDC recommended 11-to-12-year-olds receive two doses of HPV vaccine
    • IBM Watson Health and Quest Diagnostics launched IBM Watson Genomics from Quest Diagnostics

Copyright (c) 2017 The Cancer Letter Inc.